GERON CORPGERNEarnings & Financial Report
Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
GERN Q3 2025 Key Financial Metrics
Revenue
$47.2M
Gross Profit
N/A
Operating Profit
$-13.9M
Net Profit
$-18.4M
Gross Margin
N/A
Operating Margin
-29.4%
Net Margin
-39.0%
YoY Growth
67.1%
EPS
$-0.03
Financial Flow
GERON CORP Q3 2025 Financial Summary
GERON CORP reported revenue of $47.2M for Q3 2025, with a net profit of $-18.4M (-39.0% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $47.2M |
|---|---|
| Net Profit | $-18.4M |
| Gross Margin | N/A |
| Operating Margin | -29.4% |
| Report Period | Q3 2025 |
GERON CORP Annual Revenue by Year
GERON CORP annual revenue history includes year-by-year totals (for example, 2023 revenue was $237.0K).
| Year | Annual Revenue |
|---|---|
| 2023 | $237.0K |
| 2022 | $596.0K |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $164000 | $23000 | $304000 | $882000 | $28.3M | $39.6M | $49.0M | $47.2M |
| YoY Growth | -44.8% | -77.7% | 1347.6% | 2941.4% | 17138.4% | 12927.3% | 5459.6% | 67.1% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $413.0M | $394.1M | $482.1M | $449.4M | $444.9M | $562.5M | $555.2M | $567.4M |
| Liabilities | N/A | $146.1M | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | $290.6M | $247.9M | $344.9M | $306.7M | $292.3M | $268.2M | $259.5M | $248.7M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-50.8M | $-40.9M | $-62.3M | $-53.5M | $-58.9M | $-48.0M | $-27.4M | $-13.6M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M